Kornimate/medical-research-clean huggingface dataset:
incidince of acute kidney injury in children with community acquired pneumonia at assiut university children hospital

Conditions: Acute Kidney Injury

Summary: descriptive prospective observational study of incidince of acute kidney injury in children with community acquired pneumonia at assiut university children hospital

community acquired pneumonia (cap) is a prevalent cause of infectious mortality worldwide \[1, 2\]. the number of patients hospitalized with cap in the united states has been estimated to have reached one million in 2020, with similarly significant increases globally \[3\]. in egypt, it was estimated that 10% of children deaths below the age of 5 years is likely caused by pneumonia and other acute respiratory infections \[4\] acute kidney injury (aki) is an abrupt decrease in glomerular filtration rate that can lead to health consequences for children in both the short and long term \[5\]. in fact, aki may increase hospitalization length and morbidity and mortality rates for patients in the short term. meanwhile, it exposes them to an increased risk of chronic kidney disease (ckd) over time. even mild aki doubles the risk of ckd during follow-up \[6\] . aki is a common condition among hospitalized children. reports indicate that aki can exacerbate several typical pediatric disorders, such as acute gastroenteritis with an aki prevalence of around 25% \[7\], type 1 diabetes mellitus onset with a prevalence rate of approximately 45% \[8\], and acute appendicitis at roughly 7% incidence levels\[9\] . acute kidney injury (aki) frequently complicates cap; its incidence ranges from18-34 %in cap patients\[10-12\]. chawla et al., previously reported that coexisting pneumonia and aki led to worse outcomes than either pneumonia or aki alone\[13\]. even among non-severe cases diagnosed only as pneumonia, however,aki was associated with long-term mortality\[11\]. despite this evidence, the impactof aki on inhospital outcomes remains unclear for egyptian populations . adults suffering from cap present considerable risks when it comes to developing both acute kidney injury(aki)\[14-15\]and later chronic kidney disease(ckd)\[16\]; we hypothesize that there might be under-recognition regarding the prevalence of akis among children hospitalized due to cap-especially milder forms. indeed even milder forms double ckd risks during follow-ups.\[17\]thus,it becomes crucially important to detect any episodes of aki in order plan appropriate patient follow-ups.

Eligibility criteria:
inclusion criteria: - patients age \<18 years who are diagnosed with x-ray confirmed communityacquired pneumonia(cap) exclusion criteria: * we excluded patients with preexistent comorbidities potentially affecting the severity of pneumonia
treatment schistosomal portal hypertension: efficacy of endoscopy or surgery

Conditions: Schistosomiasis Mansoni; Portal Hypertension; Upper Gastrointestinal Bleeding

Summary: upper gastrointestinal bleeding (ugib) is a major cause of morbidity and mortality in patients with portal hypertension secondary to schistosomiasis mansoni. taking into account the endemic nature of schistosomiasis mansoni in our region and the high morbidity and mortality directly associated with rupture of esophageal varices and ugib in affected patients, we conducted a prospective randomized trial in patients with schistosomiasis and a history of bleeding esophageal varices. its purpose was to assess the efficacy of endoscopic treatment alone compared with the efficacy of sclerotherapy preceded by a surgical treatment: esophagogastric devascularization with splenectomy (egds).

this was a prospective, randomized, single-center study carried out at the department of clinical and surgical gastroenterology of hospital universitário professor alberto antunes, universidade federal de alagoas (hu/ufal). it was approved by the local research ethics committee (protocol #98/0039-3, code 4010000-6) and all patients provided written informed consent prior to study enrollment. patients who met relative criteria for exclusion received the current standard of care and follow-up and were analyzed as a third group in the study. over a two-year period, 79 patients were recruited for elective treatment of sph. the criteria for selection were: a) an established diagnosis of hepatosplenic schistosomiasis as the cause of portal hypertension; b) a history of ugib secondary to rupture of esophageal varices, with at least 20 days having elapsed since the most recent episode of bleeding; and c) age between 15 and 65 years. the exclusion criteria were: chronic alcoholism, defined as an alcohol intake of ≥60 g/etoh/day in men and ≥40 g/etoh/day in women; evidence of decompensated liver disease of mixed etiology or of any chronic disease that contraindicated surgery were considered absolute exclusion criteria; the relative criteria for exclusion were altered hemostasis (platelet count \ 1.5); presence of fundal varices on endoscopy.

Eligibility criteria:
inclusion criteria: * age between 15 and 65 years; * an established diagnosis of hepatosplenic schistosomiasis as the cause of portal hypertension; * a history of ugib secondary to rupture of esophageal varices, with at least 20 days having elapsed since the most recent episode of bleeding. exclusion criteria: * chronic alcoholism, defined as an alcohol intake of ≥60 g/etoh/day in men and ≥40 g/etoh/day in women; * evidence of decompensated liver disease of mixed etiology or of any chronic disease that contraindicated surgery were considered absolute exclusion criteria; * the relative criteria for exclusion were altered hemostasis (platelet count \ 1.5); * presence of fundal varices on endoscopy.

Keywords: schistosomiasis surgical treatment endoscopic treatment
performance of the poseidon system for fluid management during water-aided colonoscopy

Conditions: Colonic Disease

Summary: to validate the performance of the poseidon system™ for fluid management during water-aided endoscopic procedures in the colon.

the poseidon system is a fluid management system that is investigationally indicated to provide a pathway to control waste fluid during irrigation of the colon. the poseidon device is a manually placed and controlled device that provides support and sealing on the perimeter of an endoscope while managing fluids naturally exiting the anus, during a colonoscopy procedure. the device consists of a introducer and hand piece that allows for passage of an endoscope with valves and a retention balloon that minimize fluid passage with a single-use waste bag for collecting fluid and debris. the poseidon™ system is not yet fda 510(k) cleared.

Eligibility criteria:
inclusion criteria: 1. patients 18 years of age or greater. 2. patients that have an indication to undergo water-aided colonoscopy. 3. subjects with the ability to understand the requirements of the study, who have provided written informed consent, and who are willing and able to return for the required follow-up assessments. exclusion criteria: 1. subject unable or unwilling to provide informed consent. 2. subjects with prolapsing hemorrhoids that require intervention or hemorrhoids that have been treated within last 3 months. 3. prior tamis (trans-anal minimally invasive surgery) or tems (trans-anal micro endoscopic surgery). 4. any condition that in the opinion of the investigator would create an unsafe clinical situation that would not allow the patient to safely undergo an endoscopic procedure. 5. pregnant or lactating women or women of childbearing potential who do not employ a reliable method of contraception as judged by the investigator, and/or are not willing to use reliable contraception for the duration of study participation. 6. patient is enrolled in another trial that could interfere with the endpoint analyses of this trial.
study of the sexual health of patients treated for breast cancer and followed up in the observatory of fertility at jeanne de flandre hospital.

Conditions: Breast Cancer; Breast Neoplasms; Breast Carcinoma; Breast Tumor

Summary: study of sexual health by repeated anonymous self-administered questionnaires in patients treated for non-metastatic breast cancer and referred to jeanne de flandre hospital for possible preservation of their fertility. sexual health is affected by treatments and improves after the treatments. sexual health is influenced by multiple factors : oncology treatments received, self-esteem, body image, anxiety, depression, professional activity


Eligibility criteria:
inclusion criteria: * female from 18 years * in a relationship with a man or a woman * developing invasive carcinoma of breast cancer * planned medical therapy project by chemotherapy * followed up in the observatory of fertility * patient who gave written consent to participate in the study * insured social patient * patient willing to follow all study procedures and duration exclusion criteria: -

Keywords: breast cancer fertility preservation quality of life sexual health marital satisfaction quality of life sexual health marital satisfaction
a retrospective cohort study of hfrs

Conditions: HFRS

Summary: the goal of this retrospective cohort study is to learn about the clinial characteristics of hfrs patients, explore the risk factors of the occurrence and death of hfrs, and build a risk prediction model for hfrs.

hfrs remains an important public health issue in china, which not only poses a threat to people's physical health and safety, but also has a serious impact on social and economic development. at present, there is no unified standard for clinical prediction of the occurrence and death of hfrs. in order to better prevent and treat hfrs, this multicenter retrospective clinical study is designed to include hfrs inpatients, and collect their demographics, epidemiological history, hospitalization information, clinical manifestation, laboratory results, imaging results, treatment plan and outcome.

Eligibility criteria:
inclusion criteria: the patients must meet all of the following criteria: * inpatient with clinical diagnosis of haemorrhagic fever with renal syndrome exclusion criteria: exclude patients who meet any of the following criteria: * patients with previous chronic kidney disease * pregnant or perinatal patients * patients unsuitable for inclusion by investigators' evaluation
mri-based signatures for survival prediction in cervical cancer with radiotherapy

Conditions: Cervical Cancer; Radiotherapy; Prognostic Model; MRI

Summary: this study aims to validate the value of tumor involvement features based on mri in cervical cancer, facilitate the development of a more appropriate model for risk stratification, and help patients with varying risk profiles make appropriate decisions in treatment selection and follow-up plans.

even with the development of advanced technology, the prognosis for cc patients who received radiotherapy is still an intractable problem. almost 40% suffered disease recurrence among locally advanced patients after radiotherapy and the reported 5-year overall survival is 50-70%. the present figo staging is controversial in pre-treatment assessment, which is mainly based on physical examination. an ambiguous diagnosis leads to different treatment strategies and follow-up plans, which is associated with prognosis non-improvement. incorporation of the tumor involvement features based on the mri into pre-treatment assessment could standardize and improve the consistency and repeatability of diagnosis.

Eligibility criteria:
inclusion criteria: * (1) pathologically confirmed cc, (2) initially treated in our center exclusion criteria: * (1) lack of pre-treatment mri, (2) prior anti-tumor treatment, (3) pelvic surgery history, (4) incomplete therapy, (5) loss of follow-up
efficacy and safety of psychopharmacotherapy in patients with schizophrenia or bipolar disorders

Conditions: Schizophrenia; Bipolar Disorder

Summary: the purpose of this study is to investigate the efficacy and safety of long-term psychopharmacotherapy in schizophrenia or bipolar disorder in terms of psychopathology and side effects.

schizophrenia and bipolar disorder are renowned for chronic and deteriorating course. although atypical antipsychotics and mood stabilizers are widely used as treatment of choice for these illness based on acute efficacy and safety, long-term efficacy and safety of these agents are still open to debate. prospective follow-up study in naturalistic condition may be a useful way of elucidating cons and pros of long-term psychopharmacotherapy.in this study, efficacy and various side effects of drugs will be measured, and the possibility of neurophysiological markers will be tested by serial measurements of electroencephalographic changes.

Eligibility criteria:
inclusion criteria: * male or female patients, 18-65 years of age. * patients must have a diagnosis of schizophrenia or bipolar disorder according to the diagnostic and statistical manual of mental disorders, fourth edition (dsm-iv). * patients have not been received antipsychotics or mood stabilizers within the past 4 weeks prior to the study entry. * each patient must provide written informed consent after full explanation of study protocol, and authorized legal guardian must understand the nature of the study and must also give assent to study participation. exclusion criteria: * history of taking antipsychotics or mood stabilizers within past 4 weeks. * history of dsm-iv substance dependence. * mental retardation (iq \< 70)or patients who are not able to understand the informed consent. * definite or suspected organic mental disorders. * female patients who are not able to maintain contraception during this study * laboratory abnormalities with clinical significance * history of epilepsy or electroconvulsive therapy within the past 3 months.

Keywords: schizophrenia bipolar disorder atypical antipsychotics mood stabilizers biological markers
clinical trial to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine extended release(er)in patients with overactive bladder.

Conditions: Overactive Bladder

Summary: to evaluate the efficacy and safety of fesoterodine in comparison to tolterodine and placebo for overactive bladder


Eligibility criteria:
inclusion criteria: * adult subjects with overactive bladder symptoms (subject-reported) for greater than or equal to 3 months prior to screening/enrollment visit. * reported at least an average of 1 uui episode per 24 hours in the 3-day bladder diary prior to the randomization/baseline visit * mean urinary frequency of greater than or equal to 8 micturitions per 24 hours as verified by the 3-day bladder diary prior to randomization/baseline visit. exclusion criteria: * subjects with any condition that would contraindicate their usage of fesoterodine including: hypersensitivity to the active substance (fesoterodine fumarate) or to peanut or soya or any of the excipients, urinary retention, gastric retention, uncontrolled narrow angle glaucoma, myasthenia gravis, severe hepatic impairment (child pugh c), severe ulcerative colitis, and toxic megacolon. * subjects with clinically significant hepatic or renal disease or other significant unstable diseases. * oab symptoms caused by neurological conditions, known pathologies of urinary tract, etc. * subjects with previous history of acute urinary retention requiring catheterization, or severe voiding difficulties in the judgment of the investigator, prior to baseline.

Keywords: treatment of overactive bladder
illuminating new paths in the treatment of multiple sclerosis relapses - early and specialized rehabilitation

Conditions: Multiple Sclerosis

Summary: the overall purpose of this project is to develop and test an infrastructure that can ensure early and specialized rehabilitation for individuals with multiple sclerosis (ms) on their path to recovery from a relapse. if this project proves successful, it can therefore help optimize clinical practice and provide a significant contribution to the treatment of relapsing-remitting sclerosis.


Eligibility criteria:
inclusion criteria: * admitted to the danish ms hospitals for an inpatient rehabilitation stay * confirmed motor relapse (within the past 6 months) by a neurologist, with disability/ functional interference characterized by change in pyramidal, and/or cerebellar functional scores of 2 or higher * completed steroid or other acute relapse treatment, if prescribed * age over 18 years exclusion criteria: * more than 6 months since onset of motor relapse * medical conditions or substantial cognitive impairments that hinder participation in the study (e.g. inability to perform or understand the intensive rehabilitation) * pregnancy

Keywords: neurorehabilitation
non-pharmacological treatment and pharmacological treatment for non-acute lumbar disc herniation

Conditions: Lumbar Disc Herniation; Radiculopathy Lumbar

Summary: this study is a 2-armed parallel, multi-centered, pragmatic clinical trial that compares the comparative effectiveness of non-pharmacological treatment and pharmacological treatment for non-acute lumbar disc herniation.

this study is a multi-centered, pragmatic clinical trial that compares the comparative effectiveness of non-pharmacological treatment and pharmacological treatment for non-acute lumbar disc herniation. the participants who voluntarily signed informed consent will be randomly assigned in 1:2 ratio to non-pharmacological group and pharmacological group and will receive the 8 weeks of intervention.

Eligibility criteria:
inclusion criteria: 1. numeric rating scale (nrs) score of radiating pain or low back pain 5 or more for recent 3 serial days. 2. onset time of radiating pain occurred 3 months before enrollment. 3. radiologically diagnosed with lumbar disc herniation in lumbar spine magnetic resonance imaging (l-spine mri), which can explain lower extremity radiation pain and back pain 4. 19-69 years old 5. participants who agreed and signed informed consent form exclusion criteria: 1. spine metastasis of cancer, acute fracture of spine, or spine dislocation 2. progressive neurologic deficits or severe neurologic deficits 3. soft tissue diseases that can induce low back pain(ie. cancer, fibromyalgia, rheumatoid arthritis, gout,etc) 4. presence of chronic underlying disease which can interfere the efficacy or interpretation (ie. stroke, myocardial infarct, kidney disease, dementia, diabetic neuropathy, epilepsy, etc) 5. concurrent use of steroids, immunosuppressants, orpsychotropic medications or any other medication that can interrupt the study result 6. hemorrhagic disease, severe diabetes or taking anticoagulant drug 7. participants who took nsaids within 1 week 8. pregnant or lactating women 9. participants who had undergone lumbar surgery within 3 months 10. participants who had participated in other clinical trial within 1 month, or have plan for participation in other trial during follow up period of this trial 11. participants who can not write informed consent 12. participants who is difficult to participate in the trial according to investigator's decision
gentamicin open tibia study

Conditions: Fracture Open Tibia

Summary: local application of antibiotics directly to the traumatic wound is a promising treatment for the prevention of infection after open tibia fractures, which are a significant source of disease burden globally, particularly in low-income countries. this study aims to measure the effect of locally applied gentamicin on risk of infection for open tibial fractures in tanzania. if proven effective, local gentamicin would be a highly cost-effective strategy to reduce complications and disability from open tibial fractures that could impact care in both high- and low-income countries.

tibial shaft (shinbone) fractures are the most common major fracture of the lower leg and are frequently associated with a break in the skin known as an open fracture. because the bone is exposed by the open wound, open tibial fractures are often complicated by infection and failure of bone healing, which can lead to long-lasting disability and in some cases amputation. intravenous antibiotics administered early after injury are a well-established measure to prevent fracture-related infection (fri), but their effectiveness is limited by poor blood flow at the fracture site and inability to achieve high local concentrations with systemic administration. gentamicin applied locally within the open fracture wound is a promising adjunctive measure to reduce the risk of fri after these injuries, but there are no high-quality clinical trials evaluating its use. this will be the first randomized trial evaluating locally administered gentamicin to reduce infection in a fracture population. if efficacious, local gentamicin is likely to be a highly cost-effective preventive strategy for fri and may ultimately be cost saving. although these findings will originate from a low-income country, results may be generalizable to populations in both high and low-income countries and could therefore significantly reduce the global burden of open fractures.

Eligibility criteria:
inclusion criteria: * age\>18 years old * open tibial shaft fracture meeting the following criteria: 1. orthopaed trauma association (ota) type 42 2. primarily closable wound 3. gustilo-anderson (ga) type i, ii, or iiia exclusion criteria: * time from injury to presentation \> 48 hours * time from injury to surgery \> 7 days * aminoglycoside allergy * ga iiib or iiic open fractures * bilateral open tibial fractures * severe brain (gcs\<12) or spinal cord injury * severe vascular injury * severe burns (\>10% total body surface area (tbsa) or \>5% tbsa with full thickness or circumferential injury) * pathologic fracture * history of active limb infection, ipsilaterally * unlikely to complete follow-up